Drug Profile
Lefamulin - Nabriva Therapeutics
Alternative Names: BC-3781; BC-3781.Ac; Lefamulin-acetate; XENLETALatest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Nabriva Therapeutics
- Class Alkenes; Antibacterials; Cyclopentanes; Diterpenes; Polycyclic compounds; Small molecules; Thioglycolates
- Mechanism of Action Peptidyltransferase modulators; Protein 50S ribosomal subunit modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Community-acquired pneumonia
- Phase II Skin and soft tissue infections
- Preclinical Bacterial infections; Bone and joint infections; Nosocomial pneumonia; Osteomyelitis
- No development reported Sexually transmitted infections
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Sexually transmitted infections in USA (IV, Infusion)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Sexually transmitted infections in USA (PO, Tablet)
- 15 Oct 2019 Pooled efficacy and safety data from the phase III LEAP 1 and LEAP 2 trials in Community-acquired pneumonia released by Nabriva Therapeutics